Company profile
Medivolve Inc.
OTC: MEDVF · Healthcare · Medical - Diagnostics & Research
Canadian filerHQ Toronto, ONReports USD
#931 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 39
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ market scale, return on assets
Methodology →Revenue TTM
$682.3k
Rev growth YoY (TTM)
-93.8%
Net income (FY)
-$12.2M
Employees
25
as of 2026-08-30
Market cap
$2.7k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$508.6k686.5k CAD2023
Net income-$12.2M-16.5M CAD2023
Operating income-$2.7M-3.6M CAD2023
Total assets$1.8M2.4M CAD2023
Liabilities$13.9M18.3M CAD2023
Equity-$11.9M-15.8M CAD2023
Revenue trend
FY2017 – FY2023 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Medivolve Inc.’s revenue?
Medivolve Inc. booked $508.6k in FY2023 revenue, contracting 52% year over year — slower than 82% of Healthcare companies we track, at a -2397.5% net margin.
Peers · Healthcare
Cardax, Inc.——Lipella Pharmaceuticals Inc.——Sibannac, Inc.——DiaMedica Therapeutics Inc.35DZenith Capital Corp.——Imunon, Inc.39DKey facts
CEONeil Said
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersToronto, ON
ExchangeOTC: MEDVF
Employees25
IPO date2009-12-18
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.